Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
February 29, 2016
Kallelse till extra bolagsstämma
Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 14 mars 2016 kl 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.
Read more
February 26, 2016
Year End Report 2015
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
December 24, 2015
Affibody Licenses Albumod™ Half-life Extension Technology to MedImmune
Solna, Sweden, December 24, 2015. Affibody AB today announced that MedImmune has extended its Albumod™ platform licensing agreement
December 1, 2015
Affibody receives clinical milestone from Daiichi Sankyo
Solna, Sweden, December 1, 2015. Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo...
November 20, 2015
Interim Report – January to September 2015
August 21, 2015
Interim Report – January to June 2015
June 1, 2015
Imaging study highlighted at ASCO reveals many women may receive wrong HER2 therapy
Solna, June 1, 2015. – Affibody AB today announced the presentation of a clinical study at American Society of Clinical Oncology (ASCO).
Affibody AB and Biotest AG enter into a Research License and Option Agreement regarding the Albumod™ platform
Dreieich, Germany and Solna, Sweden – Biotest AG and Affibody AB today announced that the companies have signed a Research License and Option Agreement.
May 25, 2015
Kallelse till årsstämma
Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma tisdagen den 23 juni 2015 kl 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.
